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An imbalance between degradation and reconstruction of the aortic wall is one of the leading causes of acute aortic dissection
(AAD). Vitamin D seems an intriguing molecule to explore in the ﬁeld of AAD since it improves endothelial function and
protects smooth muscle cells from inﬂammation-induced remodeling, calciﬁcation, and loss of function, all events which
are strongly related to the aging process. We quantiﬁed 25-hydroxy vitamin D, calcium, parathormone, bone alkaline
phosphatase, and osteocalcin levels in 24 elderly AAD patients to identify a potential pathological implication of these
molecules in AAD. Median 25-hydroxy vitamin D (10.75 ng/mL, 25th–75th percentiles: 6.86–19.23 ng/mL) and calcium
levels (8.70mg/dL, 25th–75th percentiles: 7.30–8.80mg/dL) suggested hypovitaminosis D and a moderate hypocalcemia.
Thirty-eight percent of AAD patients had severe (<10 ng/mL), 38% moderate (10–20 ng/mL), and 24% mild 25-hydroxy
vitamin D deﬁciency (20–30 ng/mL). A signiﬁcant inverse correlation was observed between 25OHD and osteocalcin levels.
All the other molecules were unchanged. A condition of hypovitaminosis D associated to an increase in osteocalcin levels is
present in AAD patients. The identiﬁcation of these molecules as new factors involved in AAD may be helpful to identify
individuals at high risk as well to study preventing strategies.
1. Introduction
Increasing data suggest that vitamin D, in addition to its role
in bone metabolism, may exert important extraskeletal
eﬀects. Among diﬀerent tissues and organs, the cardiovascu-
lar system has been regarded as one of the main targets of
vitamin D actions. Epidemiological studies indicated that
serum 25-hydroxy vitamin D (25OHD) levels are inversely
associated with atherosclerosis, hypertension, coronary
artery disease, peripheral artery disease, and stroke as well
as with most of the main traditional cardiovascular risk
factors [1–7]. On the other end, clinical trials on vitamin D
supplementation failed to demonstrate a reduction in cardio-
vascular disease events leaving open the question whether
hypovitaminosis D is an epiphenomenon rather than an eti-
ological factor [8].
Recent studies suggested the existence of an inverse rela-
tionship between 25OHD levels and the presence and size of
aortic aneurysms and thoracic aortic dilatations [9–11]. The
underlying mechanisms explaining these associations are
not fully understood but probably deal with processes which
may be aﬀected by hypovitaminosis D, such as wall vessel
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inﬂammation, endothelial dysfunction, and artery wall integ-
rity. In fact, in this regard, the potential anti-inﬂammatory
properties of vitamin D [12, 13] as well as its ability to
improve endothelial function and to protect smooth muscle
cells from inﬂammation-induced remodeling, calciﬁcation,
loss of function, and senescence have been suggested in
diﬀerent studies [14–18].
An imbalance between degradation and reconstruction of
the aortic wall is also one of the leading causes of acute aortic
dissection (AAD). AAD is an acute event caused by the
formation of a tear within the artery wall and the creation
of a false lumen within aortic wall between the intima and
the media. It is associated with high morbidity and mortality
if undiagnosed or not properly treated and is mainly charac-
terized by cystic medial necrosis, elastic layer degradation,
smooth muscle cell apoptosis, and inﬂammation [19]. Any
condition which may aﬀect aortic wall integrity may thus
promote AAD.
Today, no studies assessed the vitamin D status in AAD
patients. Thus, our aim was to evaluate whether vitamin D
and vitamin D-related bone markers, which have also been
related to metabolic and cardiovascular diseases, namely,
osteocalcin (OC), parathormone (PTH), and bone alkaline
phosphatase (BAP) [20, 21], are altered in AAD, also
according to dissection localization at the ascending or
descending aorta. The identiﬁcation of new factors and
pathways potentially associated and involved in AAD
may be ﬁnally helpful to identify individuals at high risk as
well to study preventing strategies.
2. Materials and Methods
2.1. Patients. This is a retrospective investigation study of
44 consecutive AAD patients who attended the I.R.C.C.S.
Policlinico San Donato from 2005 to 2012 and were
included in the International Registry of Aortic Dissection
(IRAD) [22], according to the inclusion and exclusion cri-
teria expected by the register. The study was conducted
with the approval of local Ethics Committee (ASL Milano
2, Reference number 1409), and informed consent was
signed by each patient. To reduce the eﬀect of potential
confounding factors, the following exclusion criteria were
further applied: the known presence of generalized bone
diseases (including hyperparathyroidism, rheumatoid arthri-
tis, and Cushing’s syndrome), malignant disease, recent
major abdominal surgery, renal and liver diseases, Marfan
syndrome or other genetic disorders, lack of clinical and
biochemical data, and insuﬃcient blood samples. Thus, a
total of 24 patients were ﬁnally studied. According to
Stanford classiﬁcation, 19 were type A patients, having a
dissection in the ascending aorta (proximal dissection),
and 5 were type B, showing a dissection limited to the
descending aorta (distal dissection).
AAD were repaired using deep or moderate hypothermic
circulatory arrest and selective antegrade cerebral perfusion.
All patients were managed with open distal anastomosis.
Height, weight, medication intake, and risk factors were
recorded. Body mass index (BMI, kg/m2) was calculated.
2.2. Biochemical Assays. Serum sample was obtained after
centrifugation at 1000g for 15min and then immediately
stored at −20°C until analysis. Serum 25OHD levels were
measured by a chemiluminescence assay (Total 25OHD
assay, DiaSorin, Saluggia, Italy). The lower detection limit
was 4 ng/mL; the intra- and interassay coeﬃcients of varia-
tion (CVs) were 3.7 to 7.7% and 5.8 to 10.9%, respectively.
BAP was quantiﬁed by a direct, 2-site sandwich-type immu-
noluminometric assay utilizing two monoclonal antibodies
(BAP OSTASE, DiaSorin). The lower detection limit was
1.5μg/L; the intra- and interassay CVs were 3.2 to 4.0% and
6.5 to 8.1%, respectively. A direct, 2-site, sandwich-type
immunoluminometric test which utilizes directly coated
microparticles was used for OC detection (Osteocalcin,
DiaSorin). The lower detection limit was 0.5 ng/mL; the
intra- and interassay CVs were 3.0 to 8.0% and 4.0 to 9.0%,
respectively. 1–84 PTH was quantiﬁed with a 2-site,
sandwich-type immunoluminometric test using directly
coated microparticles (1–84 PTH assay, DiaSorin). The lower
detection limit was 4.0 pg/mL; the intra- and interassay CVs
were 3.0 to 5.9% and 5.5 to 9.0%, respectively.
All analyses were performed using the LIAISON Ana-
lyzer (DiaSorin). Calcium was quantiﬁed by a colorimetric
method using Vitros 5600 System (Ortho Clinical Diagnos-
tics, Rochester). The lower detection limit was 4.0mg/dL;
the intra- and interassay CVs were 0.04 to 0.12% and 0.9 to
1.9%, respectively.
2.3. Statistical Analysis. The normality of data distribution
was assessed by the Kolmogrov-Smirnoﬀ test. Data were
expressed as mean± standard deviation (SD), median
(25th–75th percentiles), or number and percentage. T-test,
for normal variables, or Mann–Whitney U-test, for nonpara-
metric variables, was used to compare two groups. Chi-
square test was used for categorical outcomes. For multiple
comparison (three groups), the Bonferroni correction was
used. Pearson (for normal distributed data) or Spearman
(for non-normal distributed data) correlation tests were used
to test the univariate association between variables. All statis-
tical analyses were performed using GraphPad Prism 5.0 bio-
chemical statistical package (GraphPad Software, San Diego,
CA). A p value <0.05 was considered signiﬁcant.
3. Results and Discussion
3.1. Results. The demographic, anthropometric, and clinical
characteristics of patients enrolled in the study are reported
in Table 1. In AAD patients, the median serum 25OHD levels
(10.75 ng/mL) suggest an overall condition of hypovitami-
nosis D. None of the patients had 25OHD levels higher
than 30ng/mL, the threshold for optimal vitamin D status.
The levels of 25OHD< 10ng/mL, 10–20 ng/mL, and 20–
30 ng/mL were designated as severe deﬁciency, moderate,
and mild deﬁciency, respectively. According to this classi-
ﬁcation, the 38% of AAD patients had severe 25OHD deﬁ-
ciency, 38% moderate 25OHD deﬁciency, and 24% mild
25OHD deﬁciency.
Relative to the other vitamin D-related bone turnover
markers, OC levels (17.95± 8.1 ng/mL) as well as BAP
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(7.39± 3.2mg/L) and PTH (24.40, 14.10–39.68 pg/mL)
were within the ranges of normality. After AAD patient
classiﬁcation according to 25OHD status, we observed a
signiﬁcant increase in OC concentrations (p < 0 05 for
25OHD< 10ng/mL versus 25OHD> 20ng/mL) at decreas-
ing 25OHD level.
Diﬀerently, statistically signiﬁcant diﬀerences were
observed neither in BAP and PTH levels among groups
(Figure 1) nor in any other clinical or demographic
parameters studied (Table 1). The vitamin D status of
AAD patients was further evaluated with regard to cut-
oﬀ value of 15ng/mL, which has been suggested as a more
accurate limit below which cardiometabolic dysfunction
may be observed [23–25]. In patients with 25OHD levels
lower than 15ng/mL, OC was higher (18.60, 17.13–23.38)
compared to the other group (14.80± 4.52, p < 0 05),
Table 1: Characteristics of participants included in the study.
AAD patients 25OHD< 10 ng/mL 10 ng/mL< 25OHD< 20 ng/mL 25OHD> 20 ng/mL
(n = 24) (n = 9) (n = 9) (n = 6)
Age (years) 62.67± 12.11 58.00± 14.21 61.11± 8.34 72.00± 9.59
Gender
Male (n, %) 15, 62.5 7, 77.78 8, 88.89 4, 66.66
Female (n, %) 9, 37.5 2, 22.22 1, 11.11 2, 33.33
BMI (kg/m2) 23.09± 6.09 23.23± 9.77 23.57± 2.68 25.28± 3.88
Type of dissection
A 19, 79.17 9, 100.00 6, 66.67 4, 66.67
B 5, 20.83 0, 0.00 3, 33.33 2, 33.33
First SBP 130.00± 50.88 117.22± 27.05 141.22± 70.15 79.00± 27.02
First DBP 60.00 (60.00–92.50) 66.00 (55.00–80.00) 83.75± 38.15 60.00 (60.00–92.50)
Risk factors (n, %)
Hypertension 18, 75.0 6, 66.67 6, 66.67 6, 100.00
Diabetes — — — —
Atherosclerosis 6, 25.0 2, 22.22 1, 11.11 3, 50.00
Known aortic aneurism 2, 6.3 1, 11.11 1, 11.11 0, 0.00
Prior aortic dissection — — — —
Mitral valve disease 1, 4.2 0, 0.00 1, 11.11 0, 0.00
Bicuspid aortic valve disease 3, 12.5 3, 33.33 0, 0.00 0, 0.00
Aortic valve disease 1, 4.2 1, 11.11 0, 0.00 0, 0.00
Tricuspid valve disease — — — —
Peripartum state — — — —
Other aortic disease — — — —
Cocaine abuse 1, 4.2 1, 11.11 0, 0.00 0, 0.00
Smoking 6, 25.0 3, 33.33 1, 11.11 2, 33.33
ACE inhibitors 4, 16.7 1, 11.11 2, 22.22 1, 16.67
ARB 1, 4.2 0, 0.00 0, 0.00 1, 16.67
Beta blockers 13, 54.2 6, 66.67 4, 44.44 3, 50.00
Ca-channel blockers 4, 16.7 1, 11.11 2, 22.22 1, 16.67
Diuretic 3, 12.5 0, 0.00 1, 11.11 2, 33.33
Nitroprusside 6, 25.0 0, 0.00 4, 44.44 2, 33.33
Other vasodilators 7, 29.2 4, 44.44 2, 22.22 1, 16.67
Vasopressors 1, 4.2 0, 0.00 0, 0.00 1, 16.67
25OHD (ng/mL) 10.75 (6.86–19.23) 6.29± 1.64a,b 10.60 (11.00–13.60)b 23.02± 2.55
Osteocalcin (ng/mL) 17.95± 8.14 22.26± 10.39c 17.86± 4.85 11.62± 3.57
BAP (mg/L) 7.39± 3.24 6.33± 1.78 7.56± 4.06 8.27± 3.84
PTH (pg/mL) 24.40 (14.10–39.68) 31.91± 19.65 25.32± 18.22 30.88± 22.09
Ca (mg/dL) 8.70 (7.30–8.80) 7.77± 0.99d 8.70 (8.25–8.78)c 10.75± 2.03
Data are expressed as mean ± SD, median (25th–75th percentiles), or number and proportions. BMI: body mass index; NW: normal weight; OW: overweight;
OB: obese; SBP: systolic blood pressure; DBP: diastolic blood pressure; ACE: angiotensin-converting enzyme. ARB: angiotensin II receptor blocker; 25OHD: 25-
hydroxy vitamin D; BAP: bone-speciﬁc alkaline phosphate protein; PTH: 1–84 parathormone; Ca: calcium. ap < 0 001 versus 10 ng/mL < 25OHD< 20 ng/mL;
bp < 0 001 versus 25OHD > 20 ng/mL; cp < 0 05 versus 25OHD > 20 ng/mL; dp < 0 01 versus 25OHD > 20 ng/mL.
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whereas no diﬀerences were observed in the levels of all the
other markers (data not shown). Univariate correlation
analysis clearly showed the existence of an inverse association
between 25OHD and OC (r = −0 610, p = 0 016). No corre-
lation was observed with the other parameters, instead.
Mean calcium levels suggested a mild condition of
hypocalcemia in AAD patients. As expected, calcium
levels decreased at decreasing 25OHD levels (p < 0 01 for
25OHD< 10ng/mL versus 25OHD> 20ng/mL; p < 0 05 for
10 ng/mL< 25OHD< 20 ng/mL versus 25OHD> 20 ng/mL).
Anyway, univariate correlation analyses with 25OHD and
the other parameters of calcium metabolism did not reach
the statistical signiﬁcance (25OHD: r = −0 266, p = 0 245;
OC: r = −0 126, p = 0 586; BAP: r = −0 041, p = 0 859;
PTH: r = −0 049, p = 0 834).
AAD patients were further classiﬁed according to
dissection localization. Levels of 25OHD and OC were,
respectively, higher and lower in type B compared to type
A patients, although just over the limit of statistical signiﬁ-
cance (Figure 2). None of type B patients displayed 25OHD
severe deﬁciency. BAP and PTH levels were almost the same
in the two groups, as well as calcium.
4. Discussion
The main observation of our study is that AAD patients
displayed hypovitaminosis D and there was an inverse
relationship between 25OHD and OC levels. Otherwise,
no changes in the concentrations of the other bone-related
molecules, according to vitamin D status, have been observed
in these patients.
Adequate vitamin D levels are ﬁrst of all important for
calcium absorption and thus the regulation of calcium
homeostasis. Since low concentration of 25OHD is one
of the main cause of hypocalcemia, it is not surprising to
observe a trend of decrease in calcium concentration
according to the vitamin D status of AAD patients. Other-
wise, we did not observe an increase in PTH secretion as a
compensatory mechanism to keep calcium concentration
normal, as well as any signiﬁcant correlation between
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Figure 1: Evaluation of osteocalcin, bone alkaline phosphatase (BAP), parathormone (PTH), and calcium levels in patients with acute aortic
dissection (AAD) according to plasma 25OHD concentration. AAD patients were stratiﬁed into three groups (severe deﬁciency:
25OHD< 10 ng/mL; moderate deﬁciency: 10–20 ng/mL; mild deﬁciency: >20 ng/mL) according to plasma 25OHD concentration.
∗p < 0 05 and ∗∗p < 0 01 versus 25OHD> 20 ng/mL.
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calcium and vitamin D levels. Since PTH secretion is pro-
moted by a decrease in free calcium level, it is possible that,
despite the decrease in total calcium level, free calcium did
not change. Unfortunately, in the present study, we could
measure total but not free calcium.
The unchanged levels of the bone turnover marker BAP
seemed also to suggest the lack of activation of bone-related
compensatory mechanisms in the regulation of calcium
homeostasis in AAD patients. BAP is mainly produced by
ostoblasts and plays important roles in bone matrix calciﬁca-
tion [26]. Increased BAP levels are indicative of a higher oste-
oblastic activity as a compensatory mechanism towards
increased osteoclastic activities, as observed, in osteomalacia,
a condition characterized by a slight increase in BAP levels
which are usually normalized after vitamin D treatment
[27]. Due to vitamin D deﬁciency, one could thus expect to
observe the activation of bone pathways promoting bone-
calcium resorption but this seems not to be the main conse-
quence of hypovitaminosis D in AAD patients.
In the present study, we also evaluated another bone
matrix protein, OC, a vitamin D-related product which is
released by osteoblasts and has potential role not only in
osteoblast-osteoclast interaction and bone resorption but
also in metabolism. Concerning OC, we observed the
existence of an inverse correlation between this molecule
and vitamin D. The fact that we could not observe any asso-
ciation between hypovitaminosis D and bone turnover did
not exclude the possibility that reduced vitamin D levels
may have consequences on vascular and cardiovascular
health. Patients evaluated in this study, in fact, displayed an
acute vascular event which was the result of inﬂammation-
related processes and alteration in the composition of the
media tunica of the vascular wall. Recent reports indicated
that OC is associated to arterial diseases, thus being a mole-
cule able to exert important eﬀects also on vascular tissues
which is similar to bone tissue in term of regulation of min-
eral homeostatsis [21]. In addition to OC, another molecule
mainly produced by the bone, osteopontin, emerged as a
novel player in arterial remodeling, inﬂammation, and the
promotion of ﬁbrosis, thus suggesting the same ability of
these bone-derived molecules to target the cardiovascular
system [28, 29]. Previous studies indicated a strong associa-
tion between hypovitaminosis D and the presence and extend
of arterial diseases, regardless of traditional cardiovascular
risk factors and diﬀerent cardiovascular pathologies, from
coronary artery disease, to peripheral artery disease and
aneurysms [1–7]. The association with the presence and the
extent of aneurysms has also been observed regardless of
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Figure 2: Evaluation of 25OHD, osteocalcin, bone alkaline phosphatase (BAP), parathormone (PTH), and calcium levels in patients with
acute aortic dissection (AAD) classiﬁed according to dissection localization: types A and type B.
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atherosclerosis which is considered one leading cause of
aneurysm formation, thus suggesting a potential direct eﬀect
of vitamin D action on artery walls [9–11]. In this regard,
vitamin D receptor is expressed both on endothelial as well
as on smooth muscle cells where vitamin D can control cellu-
lar survival and local inﬂammation by preventing macro-
phage inﬁltration and the consequent production of
proinﬂammatory and detrimental mediators [30, 31]. This
means that one of the main vitamin D roles at vascular level
may be its ability to play as an anti-inﬂammatory agent.
Reduced vitamin D levels have also been associated to
increased arterial stiﬀness and vascular calciﬁcation [32].
Since endothelial dysfunction, inﬂammation, and degenera-
tion of the tunica media are key event not only in simple
aneurysm formation but also in AAD, we found it interesting
to explore vitamin D and OC levels in AAD. Our study did
not describe the molecular mechanisms that could link hypo-
vitaminosis D to vascular degeneration and AAD but indi-
cated that both vitamin D and OC may play an important
pathogenetic role which needs to be further explored, any-
way. According to our data, variation in OC levels related
to that of vitamin D seemed to reﬂect the activation of local
mechanisms at vascular level rather than an alteration in
bone metabolism. In fact, this inverse correlation between
vitamin D and OC without changes in the levels of other
bone-related molecules strongly reinforced the role of OC
as an “extrabone” molecule. OC is mainly produce by osteo-
blasts where its synthesis is just regulated by vitamin D and
where it plays important activities in bone matrix mineraliza-
tion. OC exists in two main form: carboxylated, promoted by
vitamin K, and undercarboxylated. In this latter form, it has
less aﬃnities towards calcium and hydroxyapatite and it is
easily secreted and plays important endocrine activities, such
as the stimulation of insulin secretion, the increase in insulin
sensitivity, and the reduction of blood glucose levels [21].
Both forms are anyway secreted. The quantiﬁcation of total
OC, as done in our study, is an overall index of both bone-
and nonbone-related eﬀects. We also know that OC may
be produced by endothelial progenitor cells [33] which
may diﬀerentiate into OC-producing cells with a potential
involvement in vascular dysfunction and in the pathogene-
sis of AAD. Also, the vascular smooth muscle cells can diﬀer-
entiate into osteoblast-like cells [34, 35].
This has been mainly observed in the presence of inﬂam-
mation [36] that, as suggested in diﬀerent previous papers,
may be promoted by hypovitaminosis D [12, 37, 38]. To bet-
ter deﬁne the potential pathogenetic role of OC in AAD, it
would be interesting to explore on aortic tissues from AAD
patients the relationship among OC expression and vitamin
D and its receptor.
In our study, we also compared the type of AAD
according to dissection localization. Usually, type A AAD,
that is, at ascending aorta, is associated to worsen progno-
sis. By comparing the two types, we could not observe
any diﬀerence in the levels of the evaluated molecules,
although in type B patients, levels of 25OHD were higher
and OC lower compared to type A, but at the limit of the
statistical signiﬁcance, probably due to the reduced number
of type B patients.
5. Conclusions
Our study suggests that in AAD hypovitaminosis D is not
associated to changes in bone-related metabolic pathways
but is inversely related to OC which could be an interesting
molecule able to mediate the eﬀect of inadequate 25OHD
level at vascular level. Future studies exploring local vascular
mechanisms of vitamin D and OC could be helpful to better
highlight the role of these molecules in this disease. Whether
maintaining an optimal vitamin D status could be a prevent-
ing strategy needs also further analyses.
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